Objective To explore the clinical effect of stereotactic body radiotherapy(SBRT)combined with dendritic cell-cytokine-induced killer cell(DC-CIK)immunotherapy in the treatment of centrally-located locally advanced non-small cell lung cancer(LA-NSCLC).Methods A total of 113 patients with centrally-located LA-NSCLC admitted from January 2022 to March 2024 were divided into the observation group(n=56)and the control group(n=57)by using the random number table method.The observation group was treated with SBRT combined with DC-CIK immunotherapy,while the control group was treated with SBRT.The clinical efficacy of the two groups after treatment,as well as the levels of tumor markers,immune function indicators and inflammatory indicators before and after treatment,was compared.The adverse reactions during the treatment period and the short-term survival during the 12-month follow-up of the two groups were recorded.Results Compared with the control group,both objective response rate and disease control rate of the observation group were higher(P<0.05).After treatment,the levels of serum carcinoembryonic antigen,cytokeratin 19 fragment and cancer antigen 125 in both groups were lower than those before treatment,and lower in the observation group than in the control group(P<0.05,P<0.01).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the control group were lower than those before treatment,while the level of CD8+was higher than that before treatment(P<0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the observation group were higher than those before treatment and also higher than those in the control group,while the level of CD8+was lower than that before treatment and also lower than that in the control group(P<0.05,P<0.01).After treatment,the interferon-γ level in the observation group was higher than that before treatment and also higher than that in the control group,while the levels of tumor necrosis factor-α and interleukin-6 were lower than those before treatment and also lower than those in the control group(P<0.05,P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period(P>0.05).The overall survival rate of the observation group at 12-month follow-up was higher,and the median survival time was longer,as compared with the control group(P<0.05).Conclusion SBRT combined with DC-CIK immunotherapy has a definite effect in the treatment of patients with centrally-located LA-NSCLC.It can significantly improve the immune function of patients,reduce the levels of tumor markers,alleviate inflammatory responses,increase short-term survival rates,prolong survival time,and does not significantly increase adverse reactions,offering good safety and reliability.

Objective To explore the clinical effect of stereotactic body radiotherapy(SBRT)combined with dendritic cell-cytokine-induced killer cell(DC-CIK)immunotherapy in the treatment of centrally-located locally advanced non-small cell lung cancer(LA-NSCLC).Methods A total of 113 patients with centrally-located LA-NSCLC admitted from January 2022 to March 2024 were divided into the observation group(n=56)and the control group(n=57)by using the random number table method.The observation group was treated with SBRT combined with DC-CIK immunotherapy,while the control group was treated with SBRT.The clinical efficacy of the two groups after treatment,as well as the levels of tumor markers,immune function indicators and inflammatory indicators before and after treatment,was compared.The adverse reactions during the treatment period and the short-term survival during the 12-month follow-up of the two groups were recorded.Results Compared with the control group,both objective response rate and disease control rate of the observation group were higher(P<0.05).After treatment,the levels of serum carcinoembryonic antigen,cytokeratin 19 fragment and cancer antigen 125 in both groups were lower than those before treatment,and lower in the observation group than in the control group(P<0.05,P<0.01).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the control group were lower than those before treatment,while the level of CD8+was higher than that before treatment(P<0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in the observation group were higher than those before treatment and also higher than those in the control group,while the level of CD8+was lower than that before treatment and also lower than that in the control group(P<0.05,P<0.01).After treatment,the interferon-γ level in the observation group was higher than that before treatment and also higher than that in the control group,while the levels of tumor necrosis factor-α and interleukin-6 were lower than those before treatment and also lower than those in the control group(P<0.05,P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period(P>0.05).The overall survival rate of the observation group at 12-month follow-up was higher,and the median survival time was longer,as compared with the control group(P<0.05).Conclusion SBRT combined with DC-CIK immunotherapy has a definite effect in the treatment of patients with centrally-located LA-NSCLC.It can significantly improve the immune function of patients,reduce the levels of tumor markers,alleviate inflammatory responses,increase short-term survival rates,prolong survival time,and does not significantly increase adverse reactions,offering good safety and reliability.

Demoralization syndrome is a common psychological problem in patients with chronic diseases, which seriously affects their prognosis and quality of life. This article reviews the concept and assessment tools of demoralization syndrome, current status, influencing factors, and intervention measures of demoralization syndrome in chronic disease patients, so as to provide reference for clinical medical and nursing staff to develop targeted intervention measures to reduce the level of demoralization syndrome in chronic disease patients.